Navigation Links
Long-term Use of Antiepileptic Drug Vimpat® (Lacosamide) C-V Reduced Seizure Frequency and Severity and Improved Health-related Quality of Life Measures
Date:12/5/2011

or of the central nervous system. With more than 8,500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

Forward-looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.

(1) http://epilepsyfoundation.org/aboutepilepsy/

(2) http://epilepsyfoundation.org/aboutepilepsy/treatment/index.cfm

 


'/>"/>
SOURCE UCB, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Three-Year Clinical Outcomes from Use of Genous™ Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy
2. Merz research Shows Long-term Benefits for Patients With Dystonia
3. AdCare Health Systems Selects Remedi SeniorCare for Long-Term Care Pharmacy Solutions
4. Clinical Data Demonstrates Long-Term Safety of Boston Scientifics Alair[TM]Bronchial Thermoplasty System
5. Novus Scientific Announces the Worlds 1st Long-Term Absorbable Mesh as an Alternative to Non-Absorbable Synthetic Mesh
6. Rescheduled Webcast: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congress 2011
7. Webcast Alert: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congress 2011
8. NIH-Funded Study Demonstrates That Patients Receiving New CPR Devices (ResQPOD® and ResQPump™) and Cooling Have Improved Long-Term Brain Function Following Cardiac Arrest
9. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
10. Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology
11. Analysis Compares Cost-Effectiveness of Premixed Insulin Analogs to Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2 Diabetes in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in ... recently learned from a public announcement issued by Shanghai ... company listed on Shenzhen Stock Exchange, that on May ... ("Ms. Chan"), one of the shareholders of the ...
(Date:5/24/2013)... 24, 2013 In accordance with Rule 17.1 and ... of the United States Exchange Act, Echo Pharma Acquisition Limited ... Elan Corporation (NYSE: ELN). Background On ... an offer for the entire of the issued and to ... "Original Offer").  On 20 May 2013, Royalty ...
(Date:5/24/2013)... , May 24, 2013 The ... for systemic delivery of therapeutic agents has been receiving ... drug delivery showing significant promise. The crucial formulation considerations ... delivery device play a major role in the efficiency ... in the development of new formulation techniques and devices ...
Breaking Medicine Technology:China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2
... 2007 /PRNewswire/ -- DNA Therapeutics,S.A. an emerging pharmaceutical ... elucidation of a new mechanism,of action and the ... molecule Dbait. It will be,presented at the forecoming ... abstract is now available online.,The presentation itself will ...
... Potent Synergy, Activity and Patient Tolerance Support ... Spain, April 12, 2007 /PRNewswire/ -- Intarcia,Therapeutics, ... final results from a Phase 2 study ... treatment-naive patients,with genotype 1 chronic hepatitis C. ...
Cached Medicine Technology:DNA Therapeutics Reports a Novel Mechanism of Action and a,Biomarker of its Lead Molecule Dbait That Open an Innovative,Pathway-Targeting in Molecular Cancer Therapy 2DNA Therapeutics Reports a Novel Mechanism of Action and a,Biomarker of its Lead Molecule Dbait That Open an Innovative,Pathway-Targeting in Molecular Cancer Therapy 3Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 2Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 3Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 4
(Date:5/24/2013)... HealthDay Reporter , , FRIDAY, May 24 (HealthDay News) -- ... But it was a physical challenge in her childhood ... sport. "I was an 11-year-old girl with my ... diagnosed by my orthopedic surgeon," said Lewis, who has ... and the American Academy of Orthopaedic Surgeons so she ...
(Date:5/24/2013)... Pomona, Calif. (PRWEB) May 24, 2013 ... has retained its status of “Full Accreditation” for the ... (AVMA) Council on Education (COE). , “This is a ... of our hard work and student outcomes,” said College ... want to express my appreciation to the faculty, staff, ...
(Date:5/24/2013)... KC and Monica Craichy, Founders of Living Fuel, Inc ... Kyle and Austin Craichy, will be kiteboarding with members of ... , KC Craichy said he is excited to be involved ... that virtually everyone who planned to be involved is going ... meet at Matheson Hammock Park and Beach in Miami at ...
(Date:5/24/2013)... The Mirena IUD lawyers at ... the FDA has received more than 59,229 complaints since 2004 ... intrauterine birth control device known as the Mirena IUD.* , ... by the women “included ‘expulsion,’ where the IUD came out ... according to an ABC News article. “Abdominal pain is also ...
(Date:5/24/2013)... 2013 E-Dentists.com has announced the launch ... JD Media Surge, a leading medical Internet marketing agency. ... analysis service will focus on providing dentists the help ... for their competitive keywords. The dental SEO analysis covers ... based on what their competitors are doing right. The ...
Breaking Medicine News(10 mins):Health News:Top-Ranked Golfer Beats Scoliosis 2Health News:Top-Ranked Golfer Beats Scoliosis 3Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2
... found that the United States, which has the most expensive ... rich countries for quality, access and efficiency of healthcare. ... performance, to other countries and differs most notably in the ... to the studies. ,Says Commonwealth Fund president ...
... experts in India are questioning the efficacy of the ... the country. The increasing number of TB cases ... with how the DOTS strategy has been implemented, according ... has implemented various TB control programs that are used ...
... on Tuesday said that Thailand will not issue compulsory ... if pharmaceutical companies offer prices lower than those charged ... came one day after Abbott Laboratories and Thailand failed ... antiretroviral drugs Aluvia and Kaletra. ,The Thai ...
... in doctors reflects the reality in the NHS. It is ... doctors to improve the quality and experience of care for ... service. ,In virtually all of the questions patients ... answered that doctors are providing high standards of care. ...
... most common but contentious accommodation requests made by students ... entrance and licensing exams. According to a new study ... time respond to exams similarly to average students under ... there is no real evidence to suggest that the ...
... East Anglia in Norwich and Kings College in London, has ... used to find out not only the kind of drugs ... diseases. ,Lead researcher, David A. Russell, and his ... about the lifestyle of the person whose fingerprints have been ...
Cached Medicine News:Health News:Americans Get Least Value For Money In Healthcare 2Health News:Thailand Will Not Issue Compulsory Licenses for Patented Drugs 2Health News:Now Fingerprints can Be Used to Detect Drugs and Diseases Instead of Blood Samples 2
Uniquely designed, the wheelchair table has dual purposes. Not only does it add a modern look to any office, it is also a heavy-duty table that will support multiple instruments, and/or easily accomm...
... Marco Radiusgauges are available with either a ... in either monocular or binocular form. All ... one, measuring both the curvature and thickness ... The accuracy of both measurements is increased ...
... or for those seeking high quality ... is an economical, full-function instrument-delivery system. ... body offer rugged, maintenance-free service. And ... two arms provided as standard equipment--adjusts ...
... Marco could offer you a choice of two ... Chart Projector uses a halogen bulb for longer ... use. The Marco Chart Projector offers a lower ... includes a thermistor for extended bulb life. And ...
Medicine Products: